ArGEN-X hires business development director
Debbie Allen will expand take-up of Simple Antibody technology
Allen established her career at Cambridge Antibody Technology (now Medimmune), where she had management responsibility for technology, intellectual property and product out-licensing, corporate equity, co-development and cross-license agreements. She negotiated the 1999 agreement with Human Genome Sciences which led to the discovery of the monoclonal antibody Benlysta (belimumab), which has completed Phase 3 development in systemic lupus.
Since 2003, Allen has been an independent consultant to around 25 emerging biotech companies.
In her new role, she will forge alliances with biotech and pharma companies to take forward arGEN-X’s Simple Antibody platform.
